Paloma Partners’s Aimmune Therapeutics AIMT Stock Holding History

Paloma Partners’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-90,749	Closed	-$3.13M	–	2481
2020 Q3	$3.13M	Buy	+90,749	New	+$1.93M	0.08%	253
2018 Q4	–	Sell	-11,819	Closed	-$323K	–	1937
2018 Q3	$323K	Buy	+11,819	New	+$334K	0.01%	1199

Paloma Partners's AIMT Position: Q4 2020 in Review

Paloma Partners sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 90,749 shares — an estimated $3.13M sold.

Paloma Partners first reported a position in AIMT in Q3 2018 and held it in 2 quarters. The position peaked at $3.13M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Paloma Partners reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 90,749 Aimmune Therapeutics shares in Q4 2020, an estimated $3.13M.
Paloma Partners first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 2 quarters.
Paloma Partners's Aimmune Therapeutics position peaked at $3.13M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.